Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/mg229111

METABOLIC AND HORMONAL PATHWAYS CONNECTING POLYCYSTIC OVARIAN DISEASE (PCOD) TO ENDOMETRIAL CANCER

Prantika Sengupta[1], Kakali Bandhopadhay[2], Rupali Dhara Mitra[3*]

[1]Ph.D Scholar, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore, W.B., India.
[2]Professor, Department of Food Technology, Guru Nanak Institute of Technology, W.B., India.
[3*]Assistant Professor, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore, W.B., India.

***Corresponding Author:** Rupali Dhara Mitra
*E-mail: rupalidm@svu.ac.in

Abstract:
The relationship between polycystic ovarian disease (PCOD) and endometrial cancer has become a critical area of research due to the hormonal and metabolic disturbances associated with PCOD. Women with PCOD are at an increased risk of developing endometrial cancer, largely attributed to prolonged anovulation, resulting in unopposed estrogen exposure without the counterbalancing effects of progesterone. This hormonal imbalance leads to continuous endometrial proliferation, which heightens the risk of hyperplasia and subsequent cancer development. Additionally, insulin resistance and hyperinsulinemia, common in PCOD, further exacerbate the risk by promoting mitogenic and anti-apoptotic signaling pathways in the endometrial tissue. Obesity, often associated with PCOD, adds another layer of complexity by increasing peripheral estrogen production, thereby compounding the risk. Understanding the shared pathways between PCOD and endometrial cancer highlights the need for early detection, preventive strategies, and personalized therapeutic approaches to mitigate the heightened cancer risk in women with PCOD.

Keywords: Polycystic ovarian disease, Anovulation, Insulin resistance, Endometrial Cancer, Obesity

1. Introduction

Polycystic Ovary Syndrome (PCOS) affects up to 10% of women worldwide and is one of the leading causes of infertility due to chronic anovulation. PCOD is a multifactorial syndrome characterized by irregular menstrual cycles, hyperandrogenism, and polycystic ovaries, often accompanied by metabolic dysfunction such as obesity and insulin resistance. Due to the chronic nature of these imbalances, women with PCOD are at higher risk of developing endometrial cancer (EC), the most common gynecological malignancy in developed countries.

The progression from PCOD to endometrial cancer is largely driven by metabolic and hormonal disturbances that fuel endometrial hyperplasia, a precursor to endometrial cancer. These include insulin resistance, hyperinsulinemia, chronic inflammation, and persistent exposure to unopposed estrogen. The aim of this review is to explore these metabolic and hormonal pathways and understand how they contribute to increased cancer risk.

2. Pathophysiology of PCOD

2.1 Hormonal Imbalance and Androgen Excess

PCOD is marked by increased production of androgens from both the ovaries and adrenal glands, driven by hypersecretion of luteinizing hormone (LH) and insulin resistance [1]. Elevated LH levels stimulate the ovarian theca cells to produce androgens, while insulin reduces sex hormone-binding globulin (SHBG) levels, increasing the bioavailability of testosterone and other androgens.

2.2 Insulin Resistance and Metabolic Dysfunction

Insulin resistance is a hallmark of PCOD, affecting over 50% of women diagnosed with the disorder. In response, the pancreas compensates by producing excess insulin, a condition known as hyperinsulinemia [2]. Insulin acts synergistically with LH to stimulate ovarian theca cells to produce more androgens, perpetuating a cycle of hormonal dysregulation.

Hyperinsulinemia is also linked to reduced levels of SHBG, increasing the levels of free androgens in the blood, exacerbating hyperandrogenism, and further impairing reproductive function. Additionally, insulin resistance and hyperinsulinemia contribute to obesity, a significant factor in both PCOD and endometrial cancer risk [3].

2.3 Chronic Anovulation and Estrogen Dominance

Women with PCOD experience chronic anovulation, leading to prolonged exposure to unopposed estrogen. Without regular ovulation, progesterone levels remain low, and the endometrial lining becomes chronically exposed to estrogen without the counteracting effects of progesterone [4]. This hormonal imbalance creates a favorable environment for endometrial hyperplasia, a precursor to endometrial cancer.

3. Endometrial Cancer and Its Risk Factors in PCOD

Endometrial cancer (EC) is a heterogeneous disease, with two primary subtypes: estrogen-dependent Type I (endometrioid) and estrogen-independent Type II (non-endometrioid). Women with PCOD are predominantly at risk for Type I EC due to prolonged exposure to unopposed estrogen [5]. The factors contributing to this heightened risk are discussed below.

3.1 Prolonged Estrogen Exposure

The absence of regular menstrual cycles in PCOD leads to long-term unopposed estrogen exposure. Estrogen drives endometrial proliferation, and in the absence of progesterone to mediate its effects, the risk of endometrial hyperplasia and subsequent cancer increases.

3.2 Obesity and Adiposity

Obesity is a major risk factor for both PCOD and EC. Adipose tissue acts as an endocrine organ, converting androgens to estrogens via the enzyme aromatase. In obese women, this process leads to higher circulating estrogen levels, further compounding the risk of endometrial proliferation [6]. Additionally, obesity is associated with chronic inflammation and insulin resistance, both of which contribute to EC development.

Table 1: Prevalence and Characteristics of Adolescent PCOD

Characteristic	Value
Prevalence of PCOD in adolescents	5-10% of adolescent females
Common symptoms	Irregular periods, acne, hirsutism, obesity, insulin resistance
Average age of diagnosis	15-19 years
Insulin resistance prevalence	60-80% of adolescents with PCOD
Obesity prevalence in PCOD	30-50% of adolescents with PCOD
Hyperandrogenism (elevated male hormones) prevalence	70-90%



Figure: 1 ***Prevalence and Characteristics of Adolescent PCOD***

Table 1: Risk Factors and PCOD Characteristics Related to Endometrial Cancer

Risk Factor	**Prevalence in Adolescents with PCOD**	**Association with Endometrial Cancer**
Prolonged unopposed estrogen exposure	High	Strongly associated, due to lack of progesterone
Obesity	30-50%	Increases estrogen production, raises cancer risk
Insulin resistance and hyperinsulinemia	60-80%	Promotes cell proliferation in endometrial tissue
Chronic inflammation markers	Elevated in many cases	Linked to cellular changes in endometrium
Lack of regular ovulation	High	Leads to unregulated estrogen exposure

Table 2: Incidence of Endometrial Cancer in Young Women with PCOD

Age Group (yrs)	**Incidence of Endometrial Cancer (per 1,000)**	**Notes**
Adolescents (10-18)	Rare (<0.1 per 1,000)	Low incidence, but increased risk over time
18-30	0.2 per 1,000	Risk increases with prolonged PCOD
30-40	0.5 per 1,000	Higher risk without PCOD management
Over 40	1-2 per 1,000	Significantly higher risk in unmanaged PCOD

Table 3: Interventions and Their Impact on Reducing Endometrial Cancer Risk in PCOD Patients

Intervention	Impact on Risk Reduction	Notes
Hormonal	Moderate to high	Regulates menstruation, provides progesterone
Metformin (for insulin resistance)	Moderate	Reduces insulin levels, may help regulate cycles
Weight management (diet/exercise)	High	Reduces obesity, insulin resistance, and inflammation
Regular gynecological monitoring	High	Early detection of endometrial changes

The above table focused on potential correlations between PCOD and breast cancer risk in adolescent girls. While evidence linking PCOD directly to breast cancer in adolescents is limited, the table presents common characteristics of PCOD that could theoretically influence breast cancer risk later in life.



Figure: 2 ***Characteristics of Adolescent PCOD and Potential Correlation to Breast Cancer Risk***

While there is no confirmed direct correlation between adolescent PCOD and breast cancer risk during adolescence, managing PCOD-related risk factors (like obesity and insulin resistance) may help reduce the potential for breast cancer later in life. The importance of early intervention is emphasized to help mitigate long-term health risks cardiovascular disease (CVD) risk in adolescent girls. PCOD is associated with various metabolic and hormonal disturbances, which may increase the risk of cardiovascular diseases over time. While adolescents typically have a low immediate risk of CVD, early onset of PCOD-related risk factors could potentially contribute to cardiovascular issues in adulthood.

3.3 Insulin Resistance and Hyperinsulinemia

Insulin resistance and subsequent hyperinsulinemia are integral to the pathophysiology of PCOD and serve as a bridge between metabolic and reproductive dysfunction. Hyperinsulinemia promotes

endometrial proliferation through insulin and IGF-1 signaling pathways, which have mitogenic effects on endometrial cells. Insulin and IGF-1 receptors are expressed in the endometrium, and their activation promotes cell growth while inhibiting apoptosis, contributing to cancer development [7].

4. Metabolic Pathways Linking PCOD to Endometrial Cancer

4.1 Insulin and IGF-1 Signaling

The insulin and IGF-1 signaling pathways play a critical role in connecting PCOD to endometrial cancer. Hyperinsulinemia, a compensatory response to insulin resistance, stimulates insulin receptors on endometrial cells, promoting proliferation and survival . Similarly, IGF-1 receptor activation enhances cellular growth and inhibits apoptosis, creating an environment conducive to tumorigenesis [8].

Obesity exacerbates these effects by increasing insulin resistance, leading to higher insulin and IGF-1 levels in circulation. Studies have demonstrated that elevated levels of insulin and IGF-1 correlate with increased endometrial thickness and a higher risk of endometrial cancer [9].

4.2 Chronic Inflammation

Chronic low-grade inflammation is a feature of both PCOD and obesity, driven by increased levels of pro-inflammatory cytokines such as TNF-α, IL-6, and CRP [10]. These cytokines contribute to insulin resistance and promote cancer development by inducing oxidative stress, DNA damage, and abnormal cell proliferation in the endometrium.

Inflammation also stimulates the production of reactive oxygen species (ROS), which can cause DNA mutations and promote tumor initiation and progression. In women with PCOD, chronic inflammation and oxidative stress are key contributors to the development of endometrial hyperplasia and cancer [11].

4.3 Adipokines and Hormonal Dysregulation

Adipose tissue secretes bioactive molecules known as adipokines, which play a role in both metabolic and reproductive processes. In women with PCOD, altered levels of adipokines such as leptin and adiponectin have been observed. Leptin, which is elevated in obesity, promotes endometrial cell proliferation, while adiponectin, which has anti-inflammatory and insulin-sensitizing properties, is inversely related to cancer risk [12].

The dysregulation of adipokines in PCOD contributes to both metabolic dysfunction and increased endometrial cancer risk. Leptin promotes angiogenesis and cell proliferation in the endometrium, while decreased adiponectin levels lead to reduced protection against insulin resistance and inflammation [13].

5. Hormonal Pathways Connecting PCOD to Endometrial Cancer

5.1 Estrogen and Progesterone Imbalance

One of the most well-documented pathways linking PCOD to endometrial cancer is the imbalance between estrogen and progesterone. In women with PCOD, chronic anovulation results in sustained exposure to unopposed estrogen. Estrogen stimulates endometrial cell proliferation, while progesterone typically acts to counterbalance these effects by promoting cellular differentiation and endometrial shedding.

Without sufficient progesterone, the endometrium remains in a proliferative state, increasing the risk of hyperplasia and, eventually, cancer. Studies have shown that prolonged exposure to unopposed estrogen significantly increases the likelihood of developing endometrial hyperplasia, particularly in women with PCOD [14].

5.2 Hyperandrogenism and Androgen Conversion to Estrogens

Hyperandrogenism is a key feature of PCOD and plays a significant role in the pathogenesis of endometrial cancer. Androgens can be converted to estrogens through aromatase activity in adipose

tissue, particularly in obese women. This conversion further increases circulating estrogen levels, contributing to endometrial proliferation [15].
In addition, androgen receptors are expressed in the endometrium, and androgens themselves may contribute to the development of endometrial hyperplasia and cancer. Hyperandrogenism also exacerbates insulin resistance, further amplifying the metabolic dysregulation that promotes endometrial cancer risk [16].

6. Therapeutic Interventions for Reducing Cancer Risk in Women with PCOD

Given the strong metabolic and hormonal links between PCOD and endometrial cancer, therapeutic interventions aimed at reducing cancer risk are essential. The following approaches have shown promise in managing the metabolic and hormonal disturbances in PCOD, potentially reducing the risk of endometrial cancer [17].

6.1 Insulin Sensitizers

Metformin, an insulin-sensitizing drug, is commonly used in women with PCOD to improve insulin resistance and reduce circulating insulin levels. By improving insulin sensitivity, metformin may help to reduce endometrial hyperplasia and lower the risk of cancer. Studies have shown that metformin can reduce endometrial thickness and improve menstrual regularity in women with PCOD.[20,21]
In addition to metformin, thiazolidinediones (TZDs) are another class of insulin-sensitizing agents that may help to mitigate the risk of endometrial cancer by reducing insulin resistance and improving glucose metabolism.

6.2 Hormonal Therapies

Hormonal therapies, including combined oral contraceptives (COCs) and progesterone therapy, are commonly used to regulate menstrual cycles and reduce the risk of endometrial hyperplasia in women with PCOD. COCs help to lower androgen levels and protect the endometrium from unopposed estrogen by promoting regular shedding of the endometrial lining.
Progesterone therapy, either in the form of oral progestins or intrauterine devices (IUDs), is also effective in reducing the risk of endometrial hyperplasia by counteracting the proliferative effects of estrogen on the endometrium.[18].

6.3 Weight Management and Lifestyle Interventions

Weight management is a critical component of reducing both insulin resistance and cancer risk in women with PCOD. Lifestyle interventions, including dietary modifications and regular physical activity, have been shown to improve insulin sensitivity, reduce androgen levels, and decrease the risk of endometrial hyperplasia and cancer.
Weight loss, even as little as 5-10% of total body weight, can have significant effects on metabolic and reproductive outcomes in women with PCOD [19]. Soya butter is also effective in regulations of weight management [25]. Studies have demonstrated that weight loss improves insulin sensitivity, reduces hyperandrogenism, and restores ovulation in many women with PCOD . Vegan milk is also effective in reducing adiposity. Yam bean milk is very effect in regulation of high blood glucose level. (23,24)

6.4 Anti-Inflammatory Therapies

Given the role of chronic inflammation in the pathogenesis of both PCOD and endometrial cancer, anti-inflammatory therapies may be a promising approach to reducing cancer risk. Nonsteroidal anti-inflammatory drugs (NSAIDs) and dietary interventions aimed at reducing inflammation, such as the Mediterranean diet, may help to mitigate the pro-inflammatory state associated with PCOD and lower the risk of endometrial hyperplasia and cancer [20].

7. Conclusion

The metabolic and hormonal pathways connecting PCOD to endometrial cancer are complex and multifactorial. Insulin resistance, hyperinsulinemia, chronic inflammation, and prolonged exposure to unopposed estrogen are the primary drivers of endometrial hyperplasia and cancer in women with PCOD. Understanding these mechanisms is crucial for developing targeted interventions that can reduce the risk of endometrial cancer in this population.

Therapeutic strategies, including insulin sensitizers, hormonal therapies, weight management, and anti-inflammatory interventions, offer promising avenues for reducing cancer risk. As our understanding of the metabolic and hormonal underpinnings of PCOD and endometrial cancer continues to evolve, future research will be essential in refining these approaches and improving long-term outcomes for women with PCOD.

References

1. Fauser, B. C., Tarlatzis, B. C., Rebar, R. W. (2012). Consensus on women's health aspects of polycystic ovary syndrome (PCOD): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOD consensus workshop group. Fertility and Sterility, 97(1), 28-38.
2. Gallos, I. D., Coomarasamy, A. (2018). Polycystic ovary syndrome and the risk of endometrial cancer. Clinical Endocrinology, 89(5), 531-540.
3. Barry, J. A., Azizia, M. M., Hardiman, P. J. (2014). Risk of endometrial cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update, 20(5), 748-758.
4. Diamanti-Kandarakis, E., Dunaif, A. (2012). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews, 33(6), 981-1030.
5. Ehrmann, D. A. (2005). Polycystic ovary syndrome. New England Journal of Medicine, 352(12), 1223-1236.
6. Macmahon B. Risk factors for endometrial cancer. Gynecol Oncol 1974;2(2–3):122–9.
7. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod 2012;27(5):1327–31.
8. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361(9371):1810–2.
9. Lupulescu A. Estrogen use and cancer risk: a review. Exp Clin Endocrinol 1993;101: 204–14.
10. Park, I.S. Kim SI, Han Y, J Yoo Y, Seol A, Jo , J Le HA e Wang W, Han K, Song YS Risk of female-specific cancers according to obesity and menopausal status in 2.7 million Korean women: similar trends between Korean and Western women. Lancet Reg. Health West Pac .(2021) 11, 100146
11. Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol.(2019) 5, 106–107
12. Taylor AE, Ware MA, Breslow E, Pyle L (2021) 11-oxyandrogen concentrations in adolescents with polycystic ovary syndrome (PCOD). (2021) J. Endocr. Soc. 6, bvac037
13. Miller, W.L. and Auchus, R.J. (2011) The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr. Rev. 32, 81–151
14. Stein IF, Leventhal ML, 1935, Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol, 29(2): 181–191
15. Speert H, 1949, Carcinoma of the endometrium in young women. Surg Gynecol Obstet, 88(3): 332–336.
16. Harris HR, Terry KL, 2016, Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: A systematic review. Fertil Res Pract, 2(1): 1–9.
17. Cirillo, P. M., Wang, E. T., Cedars, M. I., Chen, L. M., & Cohn, B. A. (2016). Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies. *International journal of cancer*, *139*(5), 1009-1017.

18. Chang, C., Lee, S.O., Wang, R.S., Yeh, S. and Chang, T.M. (2013a). Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biol Reprod 89(1): 1–16.
19. Chang, J. H., Au, H. K., Lee, W. C., Chi, C. C., Ling, T. Y., Wang, L. M., ... & Tzeng, C. R. (2013). Expression of the pluripotent transcription factor OCT4 promotes cell migration in endometriosis. *Fertility and sterility*, *99*(5), 1332-1339
20. Sengupta P, Bandyopadhyay K, Bhattacharjee A, Mitra D R, Koley S, Bhuvaneswari M (2024) Evaluating The Role Of Low Carbohydrate Diets In Polycystic Ovarian Disease Management. African.Journal of Biological .Sciences. 6(14),5374-5378.
21. Sengupta P., Bandyopadhyay K, Mistry P, Mitra D R (2024). A Review on Adolescent Obesity and PCOD: Causes, Symptoms and Remedial Measures. Acta Scientific Nutritional Health. 8(10) 69-73.
22. Zhang,LLiu,W.,Hao,Q.,Bao,L,Wang,K.(2012). Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk. Int J Mol Sci 13(4): 4009–4020.
23. Ruj M, Biswas S, Mitra D. R. **(**2023). Phytosterol (ps) Enriched Nutella Spread From Yam Bean Milk -A Review. *Journal of Advanced Zoology, 44(*S6), 1986–1991.
24. Ash S, Saha P, Mitra D. R**.** (2023). Comparitive Nutritional Analysis Of Sweet Yam Bean (Jicama) Milk With Soya Milk -- A Review. *Journal of Advanced Zoology, 44(*S5), 2617–2623.https://doi.org/10.53555/jaz.v44iS5.3293
25. Sen S, Saha D , Mitra D. R. (2023). Exploring the Scientific Benefits of Phytesterol Enriched Soya-butter- A Comprehensive Review. *Journal of Advanced Zoology, 44*(S6), 1992–1998. https://doi.org/10.17762/jaz.v44iS6.2684